Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 558K 524K 479K 898K 61.06M 898K 6.28M 2.43M 31.15M 2.4M 2.35M 100M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17M 15.96M 14.59M 27.37M 1.86B 27.36M 191M 73.9M 949M 73.1M 71.5M 3.06B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI
20-05-29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
20-04-22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-04-21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
20-03-30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-01-08	Motion for Asset Sale Approved for Achaogen, Inc.	CI
19-12-29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
19-09-24	Final DIP Financing Approved for Achaogen, Inc.	CI
19-08-29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
19-08-13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
19-07-29	Achaogen, Inc. Announces Management Changes	CI
19-07-23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.76M 9.16M 8.38M 15.71M 1.07B 15.7M 110M 42.42M 545M 41.96M 41.04M 1.76B	8.73M 7.62M 7.15M 6.54M 12.27M 834M 12.26M 85.79M 33.13M 426M 32.78M 32.06M 1.37B
Net income	-126M -110M -103M -94.16M -177M -12.01B -177M -1.23B -477M -6.13B -472M -461M -19.76B	-187M -163M -153M -140M -262M -17.83B -262M -1.83B -708M -9.1B -700M -685M -29.34B
Net Debt	-143M -125M -117M -107M -201M -13.65B -201M -1.4B -542M -6.97B -536M -525M -22.47B	18.83M 16.44M 15.43M 14.11M 26.47M 1.8B 26.46M 185M 71.48M 918M 70.7M 69.15M 2.96B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile